PsychedelicNewsBreaks

WednesdayJun 01, 2022 1:14 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Submits IND Application

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a life-sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced that it has submitted an investigational new drug (“IND”) application with the U.S. Food and Drug Administration and Health Canada. The application is for the FDS-PEA and includes details of a planned phase 2 clinical trial of the substance for the treatment of a yet-to-be-disclosed inflammatory disorder. The announcement also noted that the company recently completed the sale of its cannabis production facility in Ontario, which completed the company’s departure from the cannabis sector and transition into becoming…

Continue Reading

WednesdayJun 01, 2022 1:09 pm

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) KWC Expanding Availability of First-of-Its-Kind Treatment – SPRAVATO(R)

Delic Holdings’ (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) subsidiary Ketamine Wellness Centers (“KWC”) , the largest ketamine therapy provider in the U.S., has expanded the availability of SPRAVATO(R) to three new cities and increased the total number of clinics offering the FDA-approved esketamine nasal spray to six. According to the update, the KWC clinics in Minneapolis, Salt Lake City and Dallas now join the Houston, Las Vegas and Seattle locations in offering SPRAVATO to their patient base. Taken with an oral supplement, SPRAVATO is for adults experiencing treatment-resistant depression (“TRD”) or depressive symptoms associated with major depressive disorder (“MDD”). “KWC…

Continue Reading

TuesdayMay 31, 2022 2:13 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Completion of Annual Filings

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has reported that, further to its news release dated May 16, 2022, the company has filed its annual financial statements, management’s discussion and analysis, and related certifications for the year ended Dec. 31, 2021, (collectively, the “annual filings”). Delic expects that the management cease trade order (the “MCTO”), which was issued on May 3, 2022, will be revoked in the coming days. While the MCTO remains in effect, the general investing public will continue to be able to trade Delic’s securities.…

Continue Reading

TuesdayMay 31, 2022 12:52 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Files IND Application for Phase-2 Trial of FSD-PEA

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the submission of an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) and Health Canada. The IND application details a planned phase 2 clinical trial of FSD-PEA for the treatment of a yet-to-be-disclosed inflammatory disorder. “Our current submissions of applications to FDA and Health Canada for FSD-201 efficacy trials represent a significant milestone in our drug development efforts,” said Zeeshan Saeed, co-founder and president of FSD Pharma. “With our elite…

Continue Reading

TuesdayMay 31, 2022 11:15 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Major Step in Advancement of CYB003 for the Treatment of Major Depressive Disorder

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced the submission of an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”). According to the update, the IND is for Cybin’s phase 1/2a first-in-human clinical trial evaluating CYB003, a proprietary deuterated psilocybin analog, for the treatment of major depressive disorder (“MDD”). “Following the successful completion of our IND-enabling work just last month, we are very excited to have reached this major milestone toward advancing CYB003 into clinical development so quickly. Based on preclinical studies, our proprietary psilocybin analog…

Continue Reading

ThursdayMay 26, 2022 2:48 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Providing Scalable, Trusted, Accessible Network of Psychedelic Clinics

Delic Holdings (CSE: DELC) (OTCQB: DELCF) is moving to fill the gaps exposed by substantial pandemic-induced disruptions of mental health services. This is amid the World Health Organization’s statistics that COVID-19 has led to a 25% increase in the number of cases of anxiety and depression globally. To fulfill its mission to heal the mental health pandemic, Delic offers education, research, and high-quality products and treatment options through wellness clinics. “The company currently operates 13 wellness clinics across nine states, making it the owner of the largest, most profitable chain of wellness clinics in the U.S. Looking ahead, Delic intends…

Continue Reading

WednesdayMay 25, 2022 2:07 pm

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Names New Independent Director to Board

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has appointed industry leader Chris Ntoumenopoulosto its board of directors. Ntoumenopoulos has deep and impressive experience in raising capital and corporate strategy, and his expertise is well-suited to support the company’s focus on advancing the delivery of psychedelic medicines. Currently managing director at 21 Corporate, an Australia-based corporate advisory firm, Ntoumenopoulos is also a strategic investment adviser at Freeman Road, an investment group specializing in health and early-stage medtech companies. Ntoumenopoulos is also a director at Race Oncology and ResApp…

Continue Reading

TuesdayMay 24, 2022 1:11 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Announces Issuance of Circular, Incentive Plan and Granting of PSUs

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced that it has issued a management information circular in respect of the annual general meeting of shareholders to be held on June 23, 2022. The circular is available on the company’s profile on SEDAR at www.SEDAR.com. In addition, to provide added flexibility to its executive compensation program, FSD Pharma on May 16, 2022, adopted an equity incentive plan (the “EIP”) pursuant to which it may grant shares, restricted share units, performance share units (“PSUs”) and…

Continue Reading

MondayMay 23, 2022 1:38 pm

PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Bringing Hope to Patients Suffering from Alzheimer’s and Potentially Other Ailments

Silo Pharma (OTCQB: SILO) is exploring the efficacy of ketamine in treating patients suffering from both Alzheimer’s and Parkinson’s disease. With more than 80% of Parkinson’s patients and 75% of Alzheimer’s patients experiencing dysphagia, difficulty or complete inability to swallow, last year, SILO entered into a joint venture with Zylö Therapeutics. Under the collaboration, the companies will explore an innovative technology – ZTI’s Z-pod transdermal technology – to develop a ketamine delivery system for those suffering from dysphagia. “In October 2021, Silo entered into a sponsored research agreement with Columbia University incorporating the work of Dr. Christine Ann Denny. According…

Continue Reading

MondayMay 23, 2022 1:00 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Partners to Help Accelerate Regulatory Pathway of CYB003

Cybin (NYSE American: CYBN) (NEO: CYBN) is moving forward with its phase 1/2a clinical trial of its proprietary deuterated psilocybin, CYB003, which, previous research shows, has the potential to effectively treat major depressive disorder (“MDD”) with significant advantages over classic psilocybin. MDD impacts over 264 million people worldwide, 1/3 to 1/2 of whom demonstrate an inadequate response to antidepressant drug treatment. Against this backdrop, Cybin focuses on finding solutions for those whose lives are impacted by MDD and other mental and emotional disorders. “The company recently completed in vivo preclinical studies of CYB003. The company plans to file an investigational…

Continue Reading